Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alteminostat (CKD-581) with Lenalidomide and Dexamethasone in Multiple Myeloma
NCT03150316Phase 1Unknown
- Sponsor
- Chong Kun Dang Holdings
- Start
- May 2017
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Alteminostat in multiple myeloma (MM), sponsored by Chong Kun Dang Holdings. Primary endpoint: Maximum Tolerated Dose up to 28 days. Status: unknown.
02
Drugs
Alteminostat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03150316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03150316.